Drug leader Dr. Reddy Laboratories Ltd. acquires 42 new drug portfolios of ANDA in the U.S. The company has come into an agreement to acquire including more than 30 generic injectable products; yet to be marketed portfolio of ANDAs, the company said in a regulatory filing.
Dr. Reddy’s Laboratories Chief Executive Officer Erez Israeli said, “The acquisition is in line with our stated strategy to significantly enhance our portfolio in our chosen growth markets.” This agreement will lead to augment the company’s injectables product portfolios in the US market along internationally, he added.
The value of total addressable market for these products in the U.S. is around $645 million for the calendar year ending in December 2018.
Read EquityPandit’s Dr. Reddy Outlook for the Week